Myeloma

After my myeloma diagnosis, each day is my own personal Olympics, filled with trials and triumph.

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for select patients newly diagnosed with multiple myeloma.

From finding reputable info to asking, “Do I really need all these drugs?” experts weighed in on important questions to ask after a myeloma diagnosis.

When I fell in love, I didn’t know my husband would end up getting cancer, but I also glad I learned that normal people like me can make a difference.

“Patients did great” with a four-drug regimen for multiple myeloma, an expert told CURE®.

I decided to receive CAR-T cell therapy for multiple myeloma when my previous regimen stopped working and now, I'm living my best life.

From a TODAY contributor opening up about breast reconstruction surgery to Arizona rep. Raúl Grijalva completing cancer treatment, here’s what’s going on in the oncology space this week.

I was diagnosed with myeloma more than two decades ago and am lucky to have support throughout.

Side effects from multiple myeloma, such as six inches of collapsed vertebrae, have made me adjust my lifestyle, but I make the most of what I can.

One expert explains how bispecific antibodies are a ‘targeted and effective’ option for patients with multiple myeloma.

Treatment with the CAR-T cell therapy Carvykti has been reported to improve survival among some patients with multiple myeloma.

"For their love, support and kindness, I am eternally grateful and blessed to have such people in our lives," said Levinson.

A beautiful tapestry reminded me to stay positive, even during a challenging time with cancer.

From Don Omar announcing being cancer free to “General Hospital” star John York talking about treatment for his two cancers, here’s what’s going on in the oncology space this week.

During the CURE® Educated Patient® Multiple Myeloma Summit, one expert explained the push to make CAR-T cell therapy available for patients sooner.

One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma.

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli.

Increased awareness and support may be one of the many ways to help decrease the impact of disparities in multiple myeloma.

As part of the CURE® Educated Patient® Summit, one expert reviewed the landscape of bispecific antibodies, such as Tecvayli, for multiple myeloma.

Quality of life may temporarily worsen after patients with myeloma receive stem cell transplants, said an expert at the Educated Patient® Multiple Myeloma Summit.

When I told my friends and family I have multiple myeloma, some of them didn't know what to do.

New drug combinations and sequences are being investigated and may improve outcomes for patients with newly diagnosed myeloma, an expert explained at the Educated Patient® Multiple Myeloma Summit.

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.

Sarclisa, Velcade, Revlimid and dexamethasone improved progression-free survival in patients with multiple myeloma who were not eligible for transplant.

Belamaf plus bortezomib and dexamethasone lengthened the time patients with relapsed or refractory myeloma lived before their disease got worse.

Blenrep, Pomalyst and dexamethasone improved progression-free survival compared to Velcade, Pomalyst and dexamethasone in patients with relapsed/refractory myeloma.

Sarclisa was granted a priority review by the Food and Drug Administration for patients newly diagnosed with multiple myeloma who are ineligible for blood transplants.

Here’s a look at therapies the FDA approved in the blood cancer space over the last few months.

Using tests to identify minimal residual disease may help determine how much treatment patients with multiple myeloma require.

Tecvayli responses were found to be slightly lower in patients with relapsed/refractory myeloma treated with another BCMA-targeted therapy.